Insurance for Biotechs: Property
by Shane Thaw
Biotechnology companies and organisations display distinctive features and, from an insurance perspective, uncommon risks. Quite apart from liability risks associated with the testing of investigational drugs, biotech
companies are faced with some unique exposures that could delay development, and possibly, the achievement of milestones. Such delays could hamper the ability of the company to raise additional funds and therefore its ability to continue as a going concern.
0 comments:
Post a Comment